The use of radioimmunotherapy in combination with bioreductive agents.
Langmuir
V K
VK
Life Sciences Division, SRI International, Menlo Park, CA 94025, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003603:Cytotoxins / Q000627:therapeutic use; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D009593:Nitroimidazoles / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D016499:Radioimmunotherapy; D014227:Triazines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003603:Cytotoxins; D018796:Immunoconjugates; D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; D014227:Triazines